. intolerance). Ibrutinib is The present gold standard therapy for individuals with relapsed/refractory disease, according to the final results of a number of period I-III trials, 115–119 but this is also changing for two most important reasons: (i) an increasing proportion of people at the moment acquire ibrutinib as frontline https://georgeu887fui3.blogpayz.com/profile